Patents Represented by Attorney, Agent or Law Firm John W. Tessman
-
Patent number: 6709810Abstract: Methods are provided for quenching undesired side reactions of pathogen inactivating compounds in biological materials. In a particular embodiment, methods are provided for quenching undesired side reactions of a pathogen inactivating compound that includes a functional group which is, or which is capable of forming, an electrophilic group. In this embodiment, the material is treated with the pathogen inactivating compound and a quencher, wherein the quencher comprises a nucleophilic functional group that is capable of covalently reacting with the electrophilic group. The electrophilic group on the pathogen inactivating compound is preferably a non-radical cationic group. In one embodiment, the pathogen inactivating compound includes a nucleic acid binding ligand and a mustard group, wherein the mustard group is capable of reacting in situ to form the electrophilic group. Preferred quenchers are thiols, such as glutathione.Type: GrantFiled: July 23, 2001Date of Patent: March 23, 2004Assignee: Cerus CorporationInventors: David Cook, Adonis Stassinopoulos
-
Patent number: 6686480Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.Type: GrantFiled: June 3, 2002Date of Patent: February 3, 2004Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6680025Abstract: A device containing a light source, a sample support and a temperature control compartment. The sample support is positioned to support multiple sample vessels for irradiation by the light source. The temperature control compartment maintains the temperature of the sample vessels within a desired range. The light source, sample support and temperature control compartment are all contained within an opaque housing.Type: GrantFiled: September 6, 2002Date of Patent: January 20, 2004Assignee: Cerus CorporationInventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
-
Patent number: 6586749Abstract: Methods and compositions are described for treating contaminants in material intended for in vivo use, and in particular blood and blood products for human use. Contaminants in blood cell preparations are inactivated prior to long term storage and transfusion. Inactivation is accomplished using a device having a unique temperature control design.Type: GrantFiled: June 25, 2002Date of Patent: July 1, 2003Assignee: Cerus CorporationInventors: George D. Cimino, Romilly John Simms
-
Patent number: 6514987Abstract: Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.Type: GrantFiled: July 2, 2000Date of Patent: February 4, 2003Assignee: Cerus CorporationInventors: David Cook, John E. Merritt, Aileen Nerio, Henry Rapoport, Adonis Stassinopoulos, Susan Wollowitz, Jan Matejovic, William A. Denny
-
Patent number: 6503699Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.Type: GrantFiled: August 16, 1999Date of Patent: January 7, 2003Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6469052Abstract: The present invention includes compositions comprising new psoralens with either a 4 ′, or 5 ′primary amino substituent and a blood product that is suitable for in vivo use. The compositions are useful for the inactivation of pathogens in blood products such as platelets and plasma.Type: GrantFiled: January 22, 2001Date of Patent: October 22, 2002Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6461567Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: GrantFiled: June 11, 2001Date of Patent: October 8, 2002Assignee: Cerus CorporationInventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
-
Patent number: 6455286Abstract: Psoralen compound compositions are synthesized which have primaryamino substitutions on the 3-, 4-, 5-, and 8-positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these psoralens result in the inactivation of pathogens which contain nucleic acid. The compounds show similar activity in test systems to 4′ and 5′ derivatives of proralen useful for inactivation of pathogens in blood products. In addition to the psoralen compositions, the invention contemplates such inactivating methods using the new psoralens.Type: GrantFiled: February 9, 2000Date of Patent: September 24, 2002Assignee: Cerus CorporationInventors: Susan Wollowitz, Aileen Nerio
-
Patent number: 6433343Abstract: Methods and compositions are described for treating contaminants in material intended for in vivo use, and in particular blood and blood products for human use. Contaminants in blood cell preparations are inactivated prior to long term storage and transfusion. Inactivation is accomplished using a device having a unique temperature control design.Type: GrantFiled: July 8, 1999Date of Patent: August 13, 2002Assignee: Cerus CorporationInventors: George D. Cimino, Romilly John Simms
-
Patent number: 6420570Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.Type: GrantFiled: January 22, 2001Date of Patent: July 16, 2002Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6410219Abstract: Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: GrantFiled: March 30, 2000Date of Patent: June 25, 2002Assignee: Cerus CorporationInventors: David Cook, Susan Wollowitz, Aileen Nerio
-
Patent number: 6270952Abstract: Methods are provided for quenching undesired side reactions of pathogen inactivating compounds in biological materials. In a particular embodiment, methods are provided for quenching undesired side reactions of a pathogen inactivating compound that includes a functional group which is, or which is capable of forming, an electrophilic group. In this embodiment, the material is treated with the pathogen inactivating compound and a quencher, wherein the quencher comprises a nucleophilic functional group that is capable of covalently reacting with the electrophilic group. The electrophilic group on the pathogen inactivating compound is preferably a non-radical cationic group. In one embodiment, the pathogen inactivating compound includes a nucleic acid binding ligand and a mustard group, wherein the mustard group is capable of reacting in situ to form the electrophilic group. Preferred quenchers are thiols, such as glutathione.Type: GrantFiled: July 6, 1998Date of Patent: August 7, 2001Assignee: Cerus CorporationInventors: David Cook, Adonis Stassinopoulos
-
Patent number: 6258319Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: GrantFiled: September 4, 1998Date of Patent: July 10, 2001Assignee: Cerus CorporationInventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
-
Patent number: 6194139Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: GrantFiled: September 28, 1999Date of Patent: February 27, 2001Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 6133460Abstract: Psoralen compound compositions are synthesized which have primaryamino substitutions on the 3-, 4-, 5-, and 8- positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these psoralens result in the inactivation of pathogens which contain nucleic acid. The compounds show similar activity in test systems to 4' and 5' derivatives of psoralen useful for inactivation of pathogens in blood products. In addition to the psoralen compositions, the invention contemplates such inactivating methods using the new psoralens.Type: GrantFiled: November 20, 1998Date of Patent: October 17, 2000Assignee: Cerus CorporationInventors: Susan Wollowitz, Aileen Nerio